Todd Carter, PhD, Chief Scientific Officer at Voyager Therapeutics, Inc., Cambridge, MA, shares an overview of the development of a novel anti-tau antibody candidate for treatment for Alzheimer’s disease (AD). After immunizing mice with pathological patient-derived tau, more than 100 antibodies were identified that targeted the pathological forms of tau, without wildtype recombinant tau binding. Upon further assessment of affinity, biophysical characteristics, efficacy in intro and in vivo, and developability, four anti-tau antibody candidates were selected. Three of the four target the same epitope in the C-terminal region of tau. This is significant, as previous tau antibodies that have failed in the clinic have targeted other regions. In studies of mice injected with pathological tau intracerebrally, Ab01 demonstrated the strongest ability to prevent tau spread, with inhibition levels of more than 70%. As tau pathology spread is closely correlated with the AD progression, it is hoped that an antibody capable to blocking pathological tau spreading would be of great clinical significance. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
